Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

487
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
487
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

358
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
358
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

74.5K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
74.5K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

550
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
550
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

335
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
335
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

333
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selenium and zinc in acute kidney injury: A systematic scoping review of speciation-resolved mechanisms, analytical validation, and translational biomarkers.

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)·2026
Same author

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same author

Reprogramming chronic wounds: the emerging role of microbiome-targeted therapies in diabetic foot ulcers.

International journal of pharmaceutics·2026
Same author

Clinical and Antimicrobial Resistance Patterns of Salmonella enterica Serovar Paratyphi A Infections in Pediatric Population.

Indian pediatrics·2026
Same author

Nanotechnology-enabled targeting strategies for neurodegenerative disorders: role of functionalized nanoparticles.

The Journal of pharmacy and pharmacology·2026
Same author

A Age Related Vascular Senescence: Mystery of Blood-brain Barrier Dysfunction in Neurodegeneration.

Molecular neurobiology·2026

Related Experiment Video

Updated: Dec 7, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.5K

Fecal Microbiota Transplant: Latest Addition to Arsenal Against Recurrent Clostridium Difficile Infection.

Monica Gulati1, Sachin K Singh1, Leander Corrie1

  • 1School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411. India.

Recent Patents on Anti-Infective Drug Discovery
|September 28, 2020
PubMed
Summary

Recurrent Clostridium difficile infection (rCDI) is challenging to treat. Fecal Microbiota Transplant (FMT) offers an effective alternative by restoring gut microbiota, though patent literature reveals knowledge gaps in its application.

Keywords:
Fecal microbiota transplantationantibioticsdysbiosismetronidazolemicrobiotarecurrent clostridium difficile

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.1K

Related Experiment Videos

Last Updated: Dec 7, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.5K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.1K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Infectious Diseases

Background:

  • Recurrent Clostridium difficile infection (rCDI) causes significant morbidity and mortality.
  • Antibiotic-induced gut dysbiosis is a primary cause of rCDI.
  • Conventional treatments like antibiotics have limitations in controlling rCDI.

Purpose of the Study:

  • To review existing patents related to Fecal Microbiota Transplant (FMT) for rCDI.
  • To identify knowledge gaps in FMT preparation, regulation, delivery, and safety.
  • To supplement patent information with non-patent literature.

Main Methods:

  • Literature review focusing on patents concerning FMT for rCDI.
  • Analysis of patent information in conjunction with non-patent scientific literature.
  • Identification of trends and gaps in FMT research and development.

Main Results:

  • Fecal Microbiota Transplant (FMT) is a successful alternative treatment for rCDI.
  • Numerous clinical trials demonstrate high success rates for FMT.
  • A limited number of patents indicate a gap in formalized knowledge regarding FMT.

Conclusions:

  • FMT is a highly effective treatment for recurrent Clostridium difficile infections.
  • Further research and patenting are needed to address gaps in FMT preparation, delivery, regulation, and safety.
  • The review highlights the need for standardized protocols and regulatory frameworks for FMT.